Home exercise using cardiac rehabilitation principles improved fitness in cancer patients

Natriuresis-guided loop diuretic titration uses spot urinary sodium measurements to tailor decongestive therapy in acute heart failure (AHF). In this sex-specific analysis of the randomized PUSH-AHF trial, investigators evaluated 310 patients (45% women) assigned to natriuresis-guided therapy versus standard of care. In men, natriuresis-guided therapy produced significantly greater mean 24-hour total natriuresis compared with standard care (443 vs 354 mmol, p = 0.004), whereas women showed no significant difference between treatment arms (357 vs 336 mmol, p = 0.533; adjusted p-interaction = 0.276). Notably, the median 24-hour natriuretic response per milligram of loop diuretic (bumetanide equivalents) was significantly lower in women receiving natriuresis-guided therapy than standard care (23 vs 52 mmol/mg, p = 0.001), while no difference was observed in men (38 vs 45 mmol/mg, p = 0.337; adjusted p-interaction = 0.009). Clinically, natriuresis guidance was associated with a 49% lower risk of 180-day all-cause mortality or HF rehospitalization in men (adjusted HR 0.51; 95% CI, 0.30–0.86; p = 0.011), but showed no benefit in women (adjusted HR 1.40; 95% CI, 0.67–2.91; p = 0.368; adjusted p-interaction = 0.026).

Platelet shortages and brief 5- to 7-day room-temperature storage limits frequently challenge hospital blood supplies and acute perioperative transfusion support. The phase 3 CHIPS trial was a multicenter, randomized, partially blinded, adaptive noninferiority trial conducted across 27 hospitals in the United States and Australia. The trial evaluated whether cold-stored platelets (CSPs; 1–6 °C, stored up to 21 days) were noninferior to standard room-temperature platelets (RTPs; 20–24 °C, stored up to 7 days) in patients with active surgical bleeding during or after cardiac surgery with cardiopulmonary bypass. Among 1,000 patients randomized 2:1 and 989 included in the primary analysis (650 CSPs, 339 RTPs; mean age 42.1 years; 67.8% male), CSPs were noninferior to RTPs for the primary 5-point hemostatic efficacy score across all storage durations (>99.9% posterior probability of noninferiority; pooled mean difference 0.09; 95% credible interval -0.06 to 0.23). Median 24-hour chest tube output was similar between groups (8.9 mL/kg for CSPs vs 8.4 mL/kg for RTPs; difference 0.4 mL/kg; 95% CI -1.0 to 1.5). Rates of arterial and venous thrombotic events, ARDS, acute kidney injury, septic shock, and mortality showed no significant differences, although surgical reexploration was higher in the CSP cohort.

Cancer survivors frequently experience a distressing co-occurring symptom cluster of persistent fatigue, sleep disruption, and chronic pain following primary therapy. The MATCH trial (Mindfulness and Tai Chi for Cancer Health) was a partially randomized patient-preference comparative effectiveness trial evaluating Mindfulness-Based Cancer Recovery (MBCR) and Tai Chi/Qigong (TCQ) in distressed cancer survivors across diverse cancer diagnoses and stages. Enrolled participants (N = 587; mean age 60.7 years) either chose an intervention or underwent randomization to MBCR or TCQ, followed by secondary randomization to immediate intervention or waitlist control. At post-intervention, both MBCR and TCQ produced statistically significant reductions in fatigue compared to waitlist controls, with mean improvements of 3.66 points (P = .036) and 3.42 points (P = .043), respectively. Pain interference improved by more than 1 point in both active groups (MBCR: P = .029; TCQ: P = .002). TCQ also yielded a statistically significant 1.9-point improvement on the sleep quality scale after multivariable adjustment (P = .004). Clinical outcomes did not differ between MBCR and TCQ, and participant preference status did not affect intervention efficacy.